By Sy Mukherjee
May 15, 2019

Hello and happy hump day, readers!

Last year, a band of health systems fed up with ever-increasing generic drug prices and a bevy of medication shortages decided they’d had enough and would take matters into their own hands. Thus Civica Rx was born. Now, the nonprofit coalition has unveiled the first treatments it will set its sights on: Antibiotics.

Civica Rx on Wednesday announced a deal with Danish generic drug maker Xellia to make forms of the injectable antibiotics vancomycin and daptomycin available to partner hospitals, which number in the hundreds. These treatments are used as antibiotics for certain patients with the most resistant forms of bacterial infections and are often in short supply, likely due to manufacturing woes.

This duo of products is just the first in a planned series of 14 treatments that Civica plans to make available to its members in the coming years. Licensing deals appear to be the primary focus at the moment—but perhaps the future could see actual independent drug development (admittedly a far more expensive and risky enterprise for a nonprofit).

Read on for the day’s news.

Sy Mukherjee
@the_sy_guy
sayak.mukherjee@fortune.com

SPONSORED FINANCIAL CONTENT

You May Like